BPC-157 10mg + TB-500 10mg + CJC-1295 (without DAC) 10mg + Ipamorelin 10mg

Full Stack — BPC-157 10mg + TB-500 10mg + CJC-1295 (Without DAC) 10mg + Ipamorelin 10mg Research Bundle UK

The Full Stack combines four widely studied research peptides across two mechanistically distinct research categories: recovery (BPC-157 and TB-500) and GH axis (CJC-1295 Without DAC and Ipamorelin). Each compound acts through a separate molecular pathway — BPC-157 through nitric oxide and VEGF signalling, TB-500 through G-actin binding and cytoskeletal dynamics, CJC-1295 through GHRHR and the Gs-cAMP-PKA cascade, and Ipamorelin through GHSR-1a and the Gq-PLC-IP3-calcium cascade — allowing all four to function as independent variables within a single comprehensive multi-pathway research protocol.

This four-compound design is suited to research programmes investigating combined tissue-recovery and GH-axis signalling in the same experimental system, where compound selection across categories requires mechanistic non-overlap.

Every compound in the Full Stack is independently tested by Janoshik laboratory. HPLC purity is confirmed at ≥98% on each of the four compounds, with LC-MS molecular identity verification. Batch-specific Certificates of Analysis are publicly accessible for all four compounds before purchase.

For laboratory handling purposes, all four lyophilised peptides may be reconstituted using BP-grade bacteriostatic water and stored at -20°C, avoiding repeated freeze-thaw cycles.

For complete mechanism detail on each compound, see the BPC-157, TB-500, CJC-1295, and Ipamorelin research guides on the Ascend Peptides UK blog, or the recovery and GH axis research peptides category pages.

WADA Status: All four compounds appear on the WADA Prohibited List, prohibited at all times.

DISCLAIMER: For in-vitro laboratory research only. Not for human consumption, therapeutic, diagnostic, or clinical use. Not classified as a medicinal product by the MHRA.